Bibliographic Details
| Title: |
The immunological bases of alemtuzumab as induction-therapy in pediatric-onset multiple sclerosis |
| Authors: |
Marco Puthenparampil, Marta Gaggiola, Francesca Rinaldi, M. Nosadini, S. Sartori, Paola Perini, Paolo Gallo |
| Source: |
Frontiers in Immunology, Vol 15 (2025) |
| Publisher Information: |
Frontiers Media S.A., 2025. |
| Publication Year: |
2025 |
| Collection: |
LCC:Immunologic diseases. Allergy |
| Subject Terms: |
pediatric-onset MS, POMS, alemtuzumab, induction therapy, multiple sclerosis, Immunologic diseases. Allergy, RC581-607 |
| More Details: |
Pediatric-Onset Multiple Sclerosis (POMS) is characterized by both white and grey matter inflammation, as well as by a higher risk of long-term physical and cognitive disability. The peculiar immunopathogenic mechanisms of POMS suggests that the use of induction therapies, including alemtuzumab (ALTZ), might be a promising approach, at least for postpuberal (> 11 yo) POMS. Although no data on the use of induction therapies in POMS are available from clinical trials currently, case series or case reports on the effect of alemtuzumab (ALTZ) have been recently published. In this review we have briefly revised the immunopathogenic features of POMS, as well as on how ALTZ might impact on them, reporting its efficacy observed in different POMS cohorts. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
1664-3224 |
| Relation: |
https://www.frontiersin.org/articles/10.3389/fimmu.2024.1509987/full; https://doaj.org/toc/1664-3224 |
| DOI: |
10.3389/fimmu.2024.1509987 |
| Access URL: |
https://doaj.org/article/fd065310b0444019a237416e43305e18 |
| Accession Number: |
edsdoj.fd065310b0444019a237416e43305e18 |
| Database: |
Directory of Open Access Journals |
